Development and Statistical Optimization of Solid Lipid Nanoparticles of Simvastatin by Using 23 Full-Factorial Design

被引:157
作者
Shah, Mayank [1 ]
Pathak, Kamla [1 ]
机构
[1] Rajiv Acad Pharm, Dept Pharmaceut, Mathura 281001, Uttar Pradesh, India
来源
AAPS PHARMSCITECH | 2010年 / 11卷 / 02期
关键词
2(3) factorial design; Pareto charts; recrystallization index; simvastatin; solid lipid nanoparticles; DIFFUSION METHOD; SYSTEM; PARAMETERS; DRUG;
D O I
10.1208/s12249-010-9414-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to develop solid lipid nanoparticles (SLNs) of simvastatin and to optimize it for independent variables (amount of glycerol monostearate, concentration of poloxamer, and volume of isopropyl alcohol) in order to achieve desired particle size with maximum percent entrapment efficiency (% EE) and percent cumulative drug release (% CDR). To achieve our goal, eight formulations (F (1)-F (8)) of SLNs were prepared by solvent injection technique and optimized by 2(3) full-factorial design. The design was validated by extra design checkpoint formulation (F (9)), and the possible interactions between independent variables were studied. The responses of the design were analyzed using Design Expert 7.1.6. (Stat-Ease, Inc, USA), and the analytical tools of software were used to draw Pareto charts and response surface plots. On the basis of software analysis, formulation F (10) with a desirability factor of 0.611 was selected as optimized formulation and was evaluated for the independent parameters. Optimized formulation showed particle size of 258.5 nm, % EE of 75.81%, with of 82.67% CDR after 55 h. The release kinetics of the optimized formulation best fitted the Higuchi model, and the recrystallization index of optimized formulation was found to be 65.51%.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 22 条
[1]   Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters [J].
Almeida, AJ ;
Runge, S ;
Muller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 149 (02) :255-265
[2]   Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design [J].
Bhavsar, MD ;
Tiwari, SB ;
Amiji, MM .
JOURNAL OF CONTROLLED RELEASE, 2006, 110 (02) :422-430
[3]  
Bolton S., 2004, Pharmaceutical statistics: practical and clinical applications
[4]  
Bozkir Asuman, 2005, Farmaco (Lausanne), V60, P840, DOI 10.1016/j.farmac.2005.06.016
[5]   Incorporation of the model drug ubidecarenone into solid lipid nanoparticles [J].
Bunjes, H ;
Drechsler, M ;
Koch, MHJ ;
Westesen, K .
PHARMACEUTICAL RESEARCH, 2001, 18 (03) :287-293
[6]   Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics [J].
Derakhshandeh, K. ;
Erfan, M. ;
Dadashzadeh, S. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 66 (01) :34-41
[7]  
Goodman, 2006, The Pharmacological Basis of Therapeutics, V11
[8]   Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization [J].
Hu, FQ ;
Yuan, H ;
Zhang, HH ;
Fang, M .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 239 (1-2) :121-128
[9]  
Lae J, 2009, AAPS PHARMSCITECH, V10, P960
[10]  
LEROUX JC, 1995, EUR J PHARM BIOPHARM, V41, P14